The drug policy debate in America is one of the most bitterly polarized public policy fights, typically framed as a clash between prohibition and decriminalization. Both camps argue passionately, and both have valid points. But they routinely ignore a fundamental prerequisite: a treatment and recovery system capable of handling the nation's soaring demand for addiction services.
Prohibitionists point to the unprecedented lethality of today's drugs. Synthetic opioids like fentanyl, up to 50 times more potent than heroin, were linked to over 55,000 overdose deaths in the past year, per CDC provisional data. These substances, they argue, demand strict controls to protect public health and safety. They have a point.
Drug reformers counter that the decades-long war on drugs has failed to curb trafficking, use, or overdose deaths. After 50 years of prohibition, drugs are cheaper, stronger, and more accessible than ever, despite massive enforcement spending. They advocate for a shift toward treating drug use as a public health issue grounded in evidence, health, equity, and human rights. They also have a point.
But regardless of which side you favor, both prohibition and reform hinge on the availability of effective treatment and recovery services. History shows that restricting supply without expanding treatment merely displaces demand. In 2005, strict controls on ephedrine and pseudoephedrine curbed domestic meth production but shifted it to Mexico, enriching cartels. More recently, as doctors cut back on opioid prescriptions, many patients turned to heroin and fentanyl. In both cases, demand didn't vanish—it migrated.
Decriminalization efforts face the same obstacle. Oregon's Measure 110, which eliminated criminal penalties for small amounts of drugs like methamphetamine and heroin, largely failed due to insufficient treatment programs. The law replaced penalties with a $100 fine that could be waived by calling a health assessment hotline. More than 95% of recipients ignored the ticket, and fewer than 1% completed the assessment. Oregon simply lacked the infrastructure to handle the influx of users seeking care.
The core problem is clear: an inadequate treatment infrastructure. While creating a new Department of Treatment and Recovery may be a bridge too far, immediate practical steps are possible. The first two essentials are people and places.
There is a critical shortage of addiction counselors, social workers, case managers, and healthcare professionals. As of 2025, over 40% of the U.S. population lives in mental health professional shortage areas. Rural counties and carceral settings, where substance use and overdose rates are highest, are especially underserved. Investing in the behavioral health workforce—through better pay, streamlined licensing, stable funding, and stronger peer support—is an urgent national priority.
The physical infrastructure is equally lacking. Inpatient detox beds, residential treatment centers, and outpatient clinics are in short supply nationwide. Nearly 80% of U.S. counties lack an opioid treatment program, the only legal source of methadone, a key FDA-approved medication for opioid use disorder. Wyoming has none. The U.S. must rapidly scale treatment capacity, extend services into underserved communities, and create safe settings for immediate care and long-term recovery.
These investments are the floor, not the ceiling, needed to transform the system. For too long, policymakers on both sides have neglected the continuum of care, leaving millions of Americans with substance use disorder without support. Expanding these services is essential to advancing any drug policy and saving lives. Building that system is no longer optional—it is the foundation on which effective drug policy must rest.
